Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients. Source
No articles found.
Orthogonal is a Socially Conscious Holding Company. As such, we only invest in co...
Orthogonal is a Socially Conscious Holding Comp...
Hepion Pharmaceuticals (Nasdaq: HEPA) is a clinical stage biopharmaceutical compan...
Hepion Pharmaceuticals (Nasdaq: HEPA) is a clin...
Vivoo is a wellness assistant that consists of urinalysis test strips and a mobile...
Vivoo is a wellness assistant that consists of ...
Kazia Therapeutics is an oncology-focused biotechnology company, developing innova...
Kazia Therapeutics is an oncology-focused biote...
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and phar...
NeoGenomics, Inc. is a high-complexity CLIA-cer...
Tactile Medical is a leader in developing and marketing at-home therapy devices th...
Tactile Medical is a leader in developing and m...
AGTC is a clinical-stage biotechnology company that uses a proprietary gene therap...
AGTC is a clinical-stage biotechnology company ...
Join the National Investor Network and get the latest information with your interests in mind.